Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov 15;9(2):482-485.
doi: 10.1016/j.ekir.2023.11.009. eCollection 2024 Feb.

An Initial Low-Dose Etelcalcetide Dosing Strategy in Hemodialysis Patients With Moderate Secondary Hyperparathyroidism is Effective and Cost-Saving

Andrea Carta  1   2 , Martina Tedesco  1   2 , Federica Mescia  1   2 , Chiara Manenti  1 , Bernardo Lucca  1 , Federica Verzeletti  1 , Alice Guerini  1   2 , Federica Gaia Terni  1   2 , Roberto Zubani  1   2 , Simona Guerini  1 , Brunella Valzorio  1 , Guido Jeannin  1 , Orsola Carli  1 , Corrado Camerini  3 , Stefano Possenti  1 , Paola Gaggia  1 , Federico Alberici  1   2
Affiliations

An Initial Low-Dose Etelcalcetide Dosing Strategy in Hemodialysis Patients With Moderate Secondary Hyperparathyroidism is Effective and Cost-Saving

Andrea Carta et al. Kidney Int Rep. .
No abstract available

Keywords: CKD-MBD; PTH; calcimimetics; etelcalcetide; hemodialysis; secondary hyperparathyroidism.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Chronic kidney disease-mineral and bone disorder parameters (parathyroid hormone, calcium and phosphate, assessed monthly) and weekly etelcalcetide dose in the low-dose and standard approaches of etelcalcetide prescription. P, phosphate; ETC, etelcalcetide. Data are represented as median (dots) and interquartile range (whiskers).
See this image and copyright information in PMC

References

    1. Bushinsky D.A., Chertow G.M., Cheng S., et al. One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism. Nephrol Dial Transplant. 2020;35:1769–1778. doi: 10.1093/ndt/gfz039. - DOI - PMC - PubMed
    1. Dörr K., Kammer M., Reindl-Schwaighofer R., et al. Randomized trial of etelcalcetide for cardiac hypertrophy in hemodialysis. Circ Res. 2021;128:1616–1625. doi: 10.1161/CIRCRESAHA.120.318556. - DOI - PubMed
    1. Cunningham J., Block G.A., Chertow G.M., et al. Etelcalcetide is effective at all levels of severity of secondary hyperparathyroidism in hemodialysis patients. Kidney Int Rep. 2019;4:987–994. doi: 10.1016/j.ekir.2019.04.010. - DOI - PMC - PubMed
    1. Karaboyas A., Muenz D., Fuller D.S., et al. Etelcalcetide utilization, dosing titration, and Chronic Kidney Disease–Mineral and Bone Disease (CKD-MBD) marker responses in US hemodialysis patients. Am J Kidney Dis. 2022;79:362–373. doi: 10.1053/j.ajkd.2021.05.020. - DOI - PubMed
    1. Tentori F., Wang M., Bieber B.A., et al. Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study. Clin J Am Soc Nephrol CJASN. 2015;10:98–109. doi: 10.2215/CJN.12941213. - DOI - PMC - PubMed

LinkOut - more resources